Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log out of your HL account

Ultragenyx Pharmaceutical Inc (RARE) USD0.001

Sell:$60.32 Buy:$60.52 Change: $1.13 (1.84%)
NASDAQ:1.01%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$60.32
Buy:$60.52
Change: $1.13 (1.84%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$60.32
Buy:$60.52
Change: $1.13 (1.84%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Contact details

Address:
60 Leveroni Ct
NOVATO
94949-5746
United States
Telephone:
+1 (415) 4838800
Website:
https://www.ultragenyx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RARE
ISIN:
US90400D1081
Market cap:
$3.54 billion
Shares in issue:
57.89 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Daniel Welch
    Independent Chairman of the Board
  • Emil Kakkis
    President, Chief Executive Officer, Director
  • Shalini Sharp
    Chief Financial Officer, Executive Vice President
  • Karah Parschauer
    Executive Vice President, General Counsel
  • Erik Harris
    Executive Vice President and Chief Commercial Officer
  • Dennis Huang
    Chief Technical Operations Officer, Executive Vice President
  • Thomas Kassberg
    Chief Business Officer, Executive Vice President
  • John Pinion
    Chief Quality Officer and Executive Vice President of Translational Sciences
  • Camille Bedrosian
    Chief Medical Officer and Executive Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.